TABLE 4.
Volumetric Growth and Progression Observed Among the Cohort of 236 Residual Meningiomas
| Growth characteristic | Category | N (%) |
|---|---|---|
| Absolute growth (cm3) | Median (IQR) | 2.2 (0.6–12.3) |
| AGR/year (cm3) | Median (IQR) | 0.11 (0.03–0.68) |
| Relative growth (%) | Median (IQR) | 82.5 (26.9–284.0) |
| RGR/year (%) | Median (IQR) | 4.3 (1.4–14.7) |
| Progression as per the RANO criteria | Yes | 132 (55.9) |
| No | 97 (41.1) | |
| Radiological progression as per tumor board | Yes | 83 (35.2) |
| No | 153 (64.8) | |
| Clinical progression | Yes | 13 (5.5) |
| No | 223 (94.5) | |
| Symptoms of progression | Visual field defect progression | 6 (42.9) |
| Headache | 4 (28.6) | |
| Sensory disturbance | 2 (14.3) | |
| Lump reappearance | 1 (7.1) | |
| Fatigue | 1 (7.1) | |
| Time to progression (mo) | Median (IQR) | 45.5 (28.4–76.8) |
AGR, absolute growth rate; RGR, relative growth rate; RANO, Response Assessment in Neuro-Oncology.